LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, Junker K, Zillmann R, Rüssel C, Hellmis E, Suttmann H, Janssen M, Marin J, Hübner A, Mathers M, Gleißner J, Scheffler M, Feyerabend S, Telle J, Klier J, Stöckle M.
Ohlmann CH, et al. Among authors: jaehnig p.
Prostate Cancer Prostatic Dis. 2022 Apr;25(4):778-784. doi: 10.1038/s41391-022-00533-6. Epub 2022 Apr 16.
Prostate Cancer Prostatic Dis. 2022.
PMID: 35430584
Free PMC article.
Clinical Trial.